Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain (AFP)

Phase II Double Blind, Randomized, Placebo Controlled, Safety and Efficacy Study of ATNC05 in Patients With Atypical Facial Pain With an Open-Label Extension Phase for Nonresponders

The purpose of the study is to test the efficacy of ATNC05 in the treatment of Atypical Facial Pain (AFP), also known as Persistent Idiopathic Facial Pain (PIFP). This research project targets patients with chronic constant facial pain and excludes patients with primarily paroxysmal pain.

Study Overview

• Status: Withdrawn
• Conditions: Atypical Facial Pain; Persistent Idiopathic Facial Pain; Atypical Trigeminal Neuralgia; Neuropathic Orofacial Pain; Neuropathic Facial Pain
• Intervention / Treatment: Drug: ATNC05; Drug: Placebo

Detailed Description

ATNC05 is a rational combination of two well-characterized drugs with decades of clinical use. The investigators hypothesize that the combination acts synergistically to reduce AFP.

The trial consists of a double-blind treatment period of twelve weeks with either Placebo or ATNC05. Subjects who do not respond to the study medication will continue on to a twelve week Open-Label extension phase, during which they will receive ATNC05.

The subjects will have six office visits during the Double-Blind phase. Subjects continuing to the Open-Label phase will have four additional visits.

Data gathering procedures include daily pain questionnaire forms, as well as questionnaires and physical examination during office visits.

• Study Type: Interventional
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• United States
  • Florida
    • North Miami, Florida, United States, 33181
      • Annette C. Toledano MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 89 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The patient is at least 18 years but no more than 89 years of age
• The patient has atypical facial pain/persistent idiopathic facial pain, as diagnosed by the 2nd Edition of The International Headache Classification (ICHD-2), section 13.18.4.
• The patient has constant pain in the face, persisting for all or most of the day (four or more hours per day) and present four days or more per week, with a severity of 5 or more (11-point scale, 0 = no pain, 10 = worst pain imaginable).
• The pain is chronic, present for at least six months.
• The patient's pain is confined at onset to a limited area on one side of the face, and is deep and poorly localized.
• The patient's pain is not associated with sensory loss or other physical signs, and diagnostic studies of face and jaws do not demonstrate any relevant abnormality.
• Patient must be willing to refrain from opioid medications during the course of the trial.
• Patients entering the study on other approved concomitant medications for pain (e.g., NSAIDS, anticonvulsants, antidepressants) must continue them as a stable regimen for at least two weeks prior to Pre-Screening and throughout the study period.
• The patient must agree to limit their rescue medications to APAP (Paracetamol/ acetaminophen).
• The patient must understand and be willing to cooperate with the study instructions, including attendance of all scheduled office visits and returning unused medication and vials.
• If the patient is a female, she must be post-menopausal, not currently pregnant or nursing, and using a reliable contraception method (e.g., intrauterine device (IUD), oral or deport contraceptive, or barrier (i.e., condom or diaphragm plus spermicide).
• The patient must sign an informed consent document indicating willingness to participate.

Exclusion Criteria:

• The patient has predominantly paroxysmal facial pain consistent with the diagnosis of classical trigeminal neuralgia or symptomatic trigeminal neuralgia.
• The patient's facial pain has an identifiable cause.
• The patient has a positive urine drug screen during the screening visit.
• The patient has a history of substance abuse and/or dependency (including but not limited to opioid and/or alcohol dependence).
• The patient has been on chronic opioid therapy or has taken opioid medication ≤ 7 days prior Pre-Screening.
• The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease. The subject has acute hepatitis or liver failure.
• The subject has a history of left ventricular hypertrophy, recent MI, angina, palpitations, dyspnea, or arrhythmia.
• The subject has used MAO Inhibitors within 30 days of enrollment.
• The patient has a history of an allergic reaction to the components in the trial medication.
• The patient is pregnant or breastfeeding.
• The patient has a heart rate of less than 60 beats per minute and/or systolic blood pressure of 90 mmHg or lower at Screening and/or medication initiation visit.
• The patient has another source of pain that is greater than AFP.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ATNC05; Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.	Drug: ATNC05; Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
Placebo Comparator: Placebo; Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.	Drug: Placebo; Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change from Baseline Period Mean in Average Pain Intensity at Weeks 9-12	The Brief Pain Inventory measures pain severity on an 11-point Likert Scale from 0 (no pain) to 10 (worst pain imaginable).	Baseline to Weeks 9-12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change from Baseline Period Mean in BPI-S Measurements (Worst Pain Intensity, Least Pain Intensity, Average Pain Intensity, Right-Now Pain Intensity, and Night Pain Intensity)	The Brief Pain Inventory - Severity measures pain severity on an 11-point Likert Scale from 0 (no pain) to 10 (worst pain imaginable).	Baseline to Weeks 1-4, Weeks 5-8, and Weeks 9-12
Mean Change from Baseline Period Mean in BPI-I Measurements (General Activity, Mood, Chewing Ability, Normal Work, Relationships, Sleep Quality, Enjoyment of Life, Talking, and Teeth Brushing)	The Brief Pain Inventory - Interference measures interference with the listed activities on an 11-point Likert Scale from 0 (does not interfere) to 10 (completely interferes)).	Baseline to Weeks 1-4, Weeks 5-8, and Weeks 9-12
Patient Global Impression of Improvement	The PGI-I measures subject's assessment of how much relief the study medication provides on a scale of 0% to 100%, in increments of 10%.	Weeks 1-4, Weeks 5-8, and Weeks 9-12
Responder Analysis of CGI-S	The Clinical Global Impression - Severity scale measures the severity of the subject's condition on a seven point scale: normal, borderline, mild, moderate, marked, severe, or extreme	Week 1, Week 4, Week 8, Week 12
Responder Analysis of CGI-I	The Clinical Global Impression - Improvement scale measures the improvement of the subject's condition on a seven-point Likert scale: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.	Week 1, Week 4, Week 8, Week 12
Number of Doses of Additional Pain Medication Taken	The amount of additional analgesic medication needed for rescue purposes.	Weeks 1-4, Weeks 5-8, and Weeks 9-12
AFP Pain Disability Index	The AFP Disability Index assesses the disability caused by AFP in various life activities. It is scored on a scale of 0-100.	Week 1, Week 4, Week 8, Week 12
Pittsburgh Insomnia Rating Scale 20	The PIRS-20 assesses the difficulty the subject has had with sleeping in the previous week. It is scored on a scale of 0-60.	Week 1, Week 4, Week 8, Week 12

Collaborators and Investigators

• Sponsor: Allodynic Therapeutics, LLC

Study record dates

Study Major Dates

• Study Start: March 1, 2014
• Primary Completion (Anticipated): March 1, 2016
• Study Completion (Anticipated): July 1, 2016

Study Registration Dates

• First Submitted: August 8, 2013
• First Submitted That Met QC Criteria: August 8, 2013
• First Posted (Estimate): August 9, 2013

Study Record Updates

• Last Update Posted (Estimate): March 13, 2014
• Last Update Submitted That Met QC Criteria: March 12, 2014
• Last Verified: March 1, 2014

More Information

Terms related to this study

• Keywords: Orofacial Pain; Tic Douloureux; Atypical Facial Pain; Persistent Idiopathic Facial Pain; Atypical Trigeminal Neuralgia; Orofacial neuropathic pain; Fothergill Disease; Prosopalgia
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Pain; Neurologic Manifestations; Disease Attributes; Neuromuscular Diseases; Stomatognathic Diseases; Mouth Diseases; Peripheral Nervous System Diseases; Cranial Nerve Diseases; Facial Nerve Diseases; Trigeminal Nerve Diseases; Facial Neuralgia; Neuralgia; Facial Pain; Trigeminal Neuralgia; Facies
• Other Study ID Numbers: AFP-001